Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 156,400 shares at $55.08 ($8.6M) on 2023-06-16, disclosed to the SEC on 2023-06-21.
Scheduled sale ($8.6M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.58 | 49,325 | $2.7M | 31.4% |
| 2 | $54.58 | 49,325 | $2.7M | 31.4% |
| 3 | $55.08 | 27,462 | $1.5M | 17.7% |
| 4 | $55.08 | 27,462 | $1.5M | 17.7% |
| 5 | $56.30 | 1,413 | $80K | 0.9% |
| 6 | $56.30 | 1,413 |
| $80K |
| 0.9% |
| Total | $54.79 avg | 156,400 | $8.6M | 100% |
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |